On 15th April 2025, the European Commission authorised lecanemab (monoclonal anti-amyloid (beta) antibody; trade name: Leqembi from Eisai and Biogen) in the European Union to treat early Alzheimer’s disease. A decision was long awaited after the positive opinion on the marketing authorisation of the medicine by the European Medicines Agency (EMA) in November 2024. The […]
Press release, March 3rd 2025 Revvity, Inc. (NYSE: RVTY), today announced the launch of EUROIMMUN’s CE-marked Anti-Measles Virus ELISA 2.0 (IgG) to support the diagnosis of a measles virus infection or to determine the immune status against measles virus. EUROIMMUN’s Anti-Measles Virus ELISA 2.0 (IgG) is the first of several assays in development expanding EUROIMMUN’s
At the end of last year, EUROIMMUN and Xpedite Diagnostics announced the start of a strategic partnership. Now the time has come: EUROArray SwiftX-traction is a rapid extraction procedure enabling the isolation of pathogen DNA for further analysis using EUROIMMUN’s EUROArrays. It has been especially developed for EUROIMMUN and is now approved worldwide for diagnostic
On 14th November 2024, the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency announced their positive opinion on the marketing authorisation of lecanemab (monoclonal anti-beta-amyloid antibody; trade name: Leqembi from Eisai and Biogen) in the European Union for the treatment of early Alzheimer’s disease in Europe. In 2023, the drug
Press release October 2nd 2024 APOE genotyping allows assessment of a patient’s risk for adverse effects from new anti-amyloid therapy for Alzheimer’s Revvity, Inc. (NYSE: RVTY), announced today the launch of the in-vitro diagnostic assay in European countries that accept the CE mark, which will enable accurate genotyping of the APOE gene. APOE genotyping is
